Modern Radiation Therapy Approaches: Targeted and Ablative Strategies

  • Theodore S. Hong


New technological advances in radiation oncology have allowed safe, high dose delivery of radiation therapy with ablative intent. In this chapter, new technologies such as intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy are discussed. Additionally, clinical use and data are presented as well.


Stereotactic Body Radiation Therapy Proton Radiotherapy Normal Tissue Complication Probability IMRT Planning Proton Beam Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Morris DE, Emami B, Mauch PM, et al. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys. 2005;62:3–19.PubMedCrossRefGoogle Scholar
  2. 2.
    Donovan E, Bleakley N, Denholm E, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82:254–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Nuttin C, A’Hern R, Rogers MS, et al. First results of a phase III multi-center randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537;vCRUK/03/005). J Clin Oncol. 2009;27:18s.CrossRefGoogle Scholar
  4. 4.
    Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010;76:326–32.PubMedCrossRefGoogle Scholar
  5. 5.
    Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Lee MT, Kim JJ, Diniwell R. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27:1585–91.PubMedCrossRefGoogle Scholar
  9. 9.
    Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58:1017–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Mahadevan A, Jain S, Goldstein M, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010;78(3):735–42. Epub 2010 Feb 18.PubMedCrossRefGoogle Scholar
  11. 11.
    Arvold ND, Niemierko A, Mamon HJ, et al. Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys. 2011;80(5):1383–90. doi: 10.1016/j.ijrobp. 2010.04.058.PubMedCrossRefGoogle Scholar
  12. 12.
    Chang EL, Shiu AS, Mendel E, et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine. 2007;7:151–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Amdur RJ, Bennett J, Olivier K, et al. A prospective, phase II study demonstrating the potential value and limitation of radiosurgery for spine metastases. Am J Clin Oncol. 2009;32(5):515–20. doi: 10.1097/COC.0b013e318194f70f.CrossRefGoogle Scholar
  14. 14.
    Dawson LA, McGinn CJ, Normolle D, et al. Escalated focal liver radiation and concurrent hepatic artery flurodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2000;8:2210–8.Google Scholar
  15. 15.
    Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53(4):810–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Dawson LA, Ten Haken RK, Lawrence TS. Partial irradiation of the liver. Semin Radiat Oncol. 2001;11:240–6.PubMedCrossRefGoogle Scholar
  17. 17.
    McGinn CJ, Ten Haken RK, Ensminger WD, et al. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol. 1998;16:2246–52.PubMedGoogle Scholar
  18. 18.
    Park HC, Seong J, Han KH, et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2002;54:150–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Cheng J. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys. 2002;54:156–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Chiba T, Tokuuye K, Matsuzaki Y, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res. 2005;11:3799–805.PubMedCrossRefGoogle Scholar
  21. 21.
    Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma with limited treatment options. Cancer. 2006;107:591–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2005;104:794–801.PubMedCrossRefGoogle Scholar
  23. 23.
    Hata M, Tokuuye K, Sugahara S, et al. Proton beam therapy for aged patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2007;69:805–12.PubMedCrossRefGoogle Scholar
  24. 24.
    Mizumoto M, Tokuuye K, Sugahara S, et al. Proton beam therapy for hepatocellular carcinoma adjacent to the porta hepatis. Int J Radiat Oncol Biol Phys. 2008;71:462–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Sugahara S, Oshiro Y, Nakayama H, et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010;76:460–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Sugahara D, Nakayama H, Fukuda K, et al. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol. 2009;185:782–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Hashimoto T, Tokuuye K, Fukumitsu N, et al. Repeated proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006;65:196–202.PubMedCrossRefGoogle Scholar
  28. 28.
    Kawashima M, Furuse J, Nishio T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol. 2005;23:1839–46.PubMedCrossRefGoogle Scholar
  29. 29.
    Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology. 2004;127:S189–93.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Radiation OncologyMassachusetts General HospitalBostonUSA

Personalised recommendations